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Abstract 
Importance: Thrombolytic therapy with intravenous alteplase within 4.5 hours of ischaemic 
stroke onset increases the overall likelihood of an excellent stroke outcome (no, or non-
disabling, symptoms). Any improvement in functional outcome distribution has value, 
however.  
 
Objective:  To estimate how the effect of alteplase on the distribution of the functional level 
varies depending on treatment delay, age and stroke severity. 
  
Data sources and study selection: We searched for all completed randomised phase 3 
trials of intravenous alteplase for treatment of acute ischaemic stroke. 
 
Data extraction and synthesis: Pre-specified individual-patient-data meta-analysis of 6756 
patients from nine randomised trials comparing alteplase versus placebo/open control. 
Ordinal logistic regression models assessed treatment differences after adjustment for 
treatment delay, age, stroke severity (measured by National Institutes of Health Stroke 
Scale; NIHSS), and relevant interaction term(s). 
 
Main outcome and measure: Ordinal analysis of the modified Rankin Score (mRS) at 3-6 
months, on which improvement is represented by numerically lower scores. 
 
Results: The maximum delay to treatment that was beneficial, when good outcome was 
defined as mRS categories 0, 0-1, 0-2 or 0-3, was at least 4.5 h after stroke onset. The 95% 
confidence interval around the common odds ratio for all dichotomisations of mRS remained 
above 1 provided that treatment was initiated within 4.5h, and there was greater benefit with 
earlier treatment. Neither age nor stroke severity significantly influenced the slope of the 
relation between benefit and time to treatment initiation. For the observed case mix of 
patients treated within 4.5 h of stroke onset, (mean 3h 20 min), the net absolute benefit of 
alteplase (ie, the difference between those who would do better if given alteplase and those 
who would do worse) was 55 patients per 1,000 treated (95% CI 13-91; p=0.004). 
 
Conclusions and Relevance: Treatment with intravenous alteplase initiated within 4.5 
hours of stroke onset increases the chance of achieving an improved level of function for all 
patients across the age spectrum including the over 80s and across all severities of stroke; 
the earlier that treatment is initiated, the greater the benefit. 
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Background 
There are essentially two widely accepted approaches to the statistical analysis of acute 
stroke outcome data. One may focus solely on good versus bad outcome, disregarding 
further details of the patient’s functional status. Thus, one may consider patients with an 
“excellent” outcome to be of equal value to those with a “good” outcome but otherwise 
patients left with only “fair” outcome, “poor” outcome or even death are all considered just as 
having a bad outcome.   Alternatively, one could consider if treatment shifted the entire 
distribution of outcomes favourably, ie one seeks an increase in the average likelihood of 
achieving a better outcome.1 The traditional measure for a good stroke outcome, mRS 0-1, 
considers the former whereas ordinal approaches generally consider the latter.  
 
These two approaches are not mutually incompatible, however, and both should usually be 
considered. Indeed, a good clinician could incorporate elements of each approach when 
counselling patients or relatives prior to offering intravenous thrombolysis for stroke. 
 
The recent individual patient data (IPD) meta-analysis of 6756 patients from nine 
thrombolysis trials reported treatment differences that dichotomised outcomes into the 
“excellent” (mRS 0-1) and “bad” (death: mRS 6 versus mRS 0-5) ends of the scale.2  In 
those analyses, intravenous alteplase was shown to improve significantly the overall odds of 
an excellent stroke outcome (mRS 0-1) when delivered within 4·5 h of stroke onset. That 
analysis showed that earlier treatment resulted in larger benefit of treatment, with – at any 
given time delay - treatment advantages that were similar irrespective of age or stroke 
severity. However, alteplase was also shown to increase the absolute risk of fatal 
intracranial haemorrhage within the first week by about 2%, with no significant effect on 
other early causes of death but perhaps partly offset by later causes of death.  
 
An earlier IPD analysis carried out in 2010, which included data from 8 of the same 9 trials, 
suggested that 3 month mortality was increased when treatment was initiated beyond 4.5h 
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after stroke onset,3 but in the updated analysis this trend with treatment delay lost statistical 
significance. However, death is just one potential adverse outcome: severe or even 
moderate disability will be considered by some patients to be as undesirable as death, or 
perhaps worse;4 and others still may consider any loss of dependence as a poor outcome.5 
In addition, differences in the length of hospital stay, and the cost of care, increase 
substantially and monotonically with measures of disability.6   To help clinicians to discuss 
with their patients the pros and cons of a treatment that carries both potential risks and 
benefits, we now report various analyses that consider the full range of functional states 90-
180 days after stroke. 
 
For most circumstances in which the outcome measure involves a series of 3 or more levels 
of ordinal outcomes, ordinal analysis is generally considered a statistically powerful 
approach by expert groups for circumstances where treatment effects are not expected to 
concentrate at one end of the disability scale.1,7 For treatments that may have a dual effect 
(the extreme example would be ‘kill or cure’), risk and benefit may each be more reliably 
detected by a dichotomised analysis (“symptom-free survival”), but if survival despite 
continued symptoms is a desirable health state to some patients, then an analysis that 
considers all categories (symptom-free survival, symptomatic survival, severe disability, 
death) may be more discriminating for net benefit.1,8 Since it is well established that later 
treatment (eg 4.5 to 6 hours after stroke onset) is associated with reduced benefit and with a 
trend at least towards lower 90-day survival, we can surmise that the greatest treatment 
delay at which net benefit persists may be shorter than the ~5 hour window when indexed by 
defining a good outcome as mRS 0-1.2 However, the more sensitive ordinal analysis offers 
the opportunity to refine the characterisation of the time period when patients benefit from 
alteplase therapy. The aim of this report is to present the results from the pre-defined ordinal 
analyses,9 and to put them in context with the already published main dichotomous ones.2 
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Methods 
The data sources and analysis methods have been described in detail previously, 
particularly the approach used to determine the influence of time from stroke onset on the 
outcome mRS 0-1 versus 2-6.2,9 For each other dichotomy of mRS, ie 0 versus 1-6, 0-2 
versus 3-6 etc, we repeated that approach. We also examined the full range of the mRS to 
assess the common odds of better outcome with intravenous alteplase versus control, using 
ordinal logistic regression.10 The use of the common odds ratio invokes assumptions about 
the consistency of the treatment effect across the spectrum of outcome scores, but carries 
advantages over its alternatives in terms of greater statistical power and ease of adjustment 
for baseline prognostic factors.1,8 However, we also applied the ordinal approach of Howard 
et al (2012)11  to estimate the net benefit of treatment (ie, the expected number who would do 
better if given alteplase minus the expected number who would do worse), among a cohort 
with the case mix included in the pooled trials. 
 
As described previously, regression models, which for dichotomised outcomes were 
stratified by trial, were adjusted for allocation to alteplase, treatment delay, age, stroke 
severity (as measured by the National Institutes of Health Stroke Scale; NIHSS), and 
relevant interaction term(s).9 Eight trials assessed functional outcome after 3 months using 
the modified Rankin Scale whereas the third international stroke trial, IST-3, applied the 
Oxford Handicap Scale to patients at 6 months’ follow-up.12-18 Whereas our publication on 
mRS 0-1 described functional outcome at 3-6 months but mortality only at three months, for 
the present analyses we have used mortality and functional outcome at 6 months for IST-3 
patients but at 3 months for all other trials’ patients (noting that a 3-month assessment was 
not performed in IST-3).2 Analyses were performed using SAS version 9.3 (SAS Institute, 
Cary) and R version 2.11.1 (www.R-project.org). 
 
Where relevant, the significance of 3-way interaction terms was assessed using the 
likelihood ratio test of the change in deviance between two nested models that differed only 
!! 7!
by the relevant interaction term. We made no adjustment for multiplicity: ordinal analysis was 
planned9 and the primary dichotomised analysis of mRS 0-1 achieved statistical significance.  
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Results 
The baseline characteristics of the patient population have been published previously.2 
There were 6756 patients with mean (SD) age 71 ± 13 years, NIHSS 12 ± 7 and onset to 
treatment delay 4.0 ± 1.2 hours. 
 
The average odds of achieving a better stroke outcome in alteplase-allocated compared with 
control-allocated patients across the whole 6-hour window (mean delay 4.0 h) diminished as 
the selected cutpoint used to define “better” outcome shifted from least symptomatic (mRS 
0, OR 1.40, 95% CI: 1.22–1.62) to greatest residual disability (mRS 5, OR 0.93, 95% CI: 
0.82–1.06; eFigure 1).   The p-value for the assumption of a common odds ratio is <0.0001, 
suggesting there is heterogeneity of the odds ratios across the various dichotomies.  This 
heterogeneity between mRS thresholds would appear to be attributable to a general 
downward shift in the odds of better outcome at higher mRS thresholds, while the pattern of 
poorer outcomes with longer delays in the time to treatment was relatively consistent across 
the mRS spectrum. 
 
For each of the possible dichotomisations of mRS, earlier treatment was associated with 
bigger proportional benefits; this interaction with treatment delay was conventionally 
statistically significant (p<0.05) for each of the comparisons 0-1 v 2-6 through to 0-4 v 5-6, 
and, despite being qualitatively similar, with relatively few patients with mRS of either 0 or 6 
was not statistically significant for mRS 0 vs 1-6 or mRS 0-5 vs 6 (Figure 1). The maximum 
delay between stroke onset and treatment that was associated with a significantly positive 
treatment effect was at least 4.5 hours for each dichotomisation of the mRS scale classifying 
0, 0-1, 0-2 or 0-3 as good outcome. For mRS 0-4 versus 5-6 or 0-5 versus 6 (death), it was 
not established that alteplase significantly increased the overall odds of a better outcome 
(eFigure 1) nor that earlier treatment (even at 1 hour) was associated with a clear benefit 
(Figure 1).  
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After combining the results of the alternative dichotomous analyses to model the average 
odds ratio for any upwards shift in mRS, treatment initiation within 4.5 hours was associated 
with statistically significant net benefit, with earlier treatment resulting in bigger proportional 
benefits (Figure 2). Given treatment delay, neither patient age or baseline stroke severity 
significantly altered the effect of alteplase on the odds of an improved outcome (eFigure 2); 
nor did stroke severity significantly alter the relationship between treatment delay and the 
odds of an improved outcome with alteplase (p = 0.12). The test for a three-way interaction 
among treatment, treatment delay and age as a continuous variable had a p value of 0.0019, 
in the direction of older age lengthening the window during which intravenous alteplase may 
be effective (eFigure 3). The window remains open until at least 4.5 hours for both younger 
and more elderly patients. 
 
The observed frequencies of patients in various outcome strata according to treatment delay 
and baseline stroke severity, without adjustment for other characteristics, are shown in 
eFigures 4 and 5. 
 
An ordinal analysis, avoiding the proportionality assumption,11 of the patients treated within 
4.5 hours of stroke onset (mean delay 3 hours 20 minutes), where benefit is expressed as 
any improvement in one or more divisions of the mRS, found that a net 55 patients (95% CI 
13, 91) per 1,000 treated were better with alteplase, p=0.004. Earlier treatment was better: 
within 3 hours (average 2 h 20 m) net benefit was 122 patients (95% CI 61, 171) per 1,000 
treated whereas initiating treatment beyond 4.5 hours (mean 5 hours 20 minutes) revealed a 
net benefit of only 20 patients (95% CI -31, 75) per 1,000 treated, p=0.45. 
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Discussion 
Patients with acute ischaemic stroke show wide variation in the severity and range of their 
symptoms at presentation. Their functional outcomes are also diverse. The categories of the 
modified Rankin Scale capture this diversity well. Dichotomisation of the scale at mRS 0-1 
(excellent outcome) versus 2-6 (poorer outcome), or at 0-2 (independent) versus 3-6 
(dependent or dead) simplifies the presentation of the impact of treatment but implying cure 
or near cure oversimplifies clinical reality for most patients. Patients want to know if 
treatment will make a noticeable difference to their functional outcome: many would regard 
an improvement by any step in mRS level as worthwhile, though they would not necessarily 
weight all transitions as equal.5  
 
In addition, such simplification tends to lead to situations where clinicians are eager to 
identify the “good responders”, whereas the reality may well be that the majority of patients 
improve somewhat, with a few showing a major improvement (or major deterioration and 
early death). An overemphasis on only treating those likely to have a major improvement 
may lead to the situation where the net benefit of thrombolysis would be lost. 
 
Our analysis reveals that if good outcome is represented by any contiguous group of mRS 
levels from 0 (asymptomatic) down to 3 (requiring help for activities of daily living), then the 
onset to treatment time window in which benefit is statistically more likely with alteplase is at 
least 4.5 hours, though earlier treatment is better and by 4.5 hours the benefit is becoming 
small. Treatment with intravenous alteplase initiated within 4.5 hours reduces the proportion 
of patients with mRS 4 or higher: there will be fewer patients who cannot walk independently 
or require help with basic toileting. We did not find that intravenous alteplase alters mRS 0-4 
versus 5-6, nor, as we have previously shown and examined in greater detail,2 did we have 
evidence that it alters survival excepting the small excess of early fatal bleeding (Figure 1 
and eFigure 1). Thus, intravenous alteplase appears to enhance chances of achieving a 
good outcome by more than it improves the chances of achieving a merely acceptable 
!! 11!
outcome, which may be attractive to patients. Analysis that relies on a common odds ratio to 
combine all possible dichotomies of mRS is compromised by violation of the assumption that 
these ratios are similar. However, though the odds ratios diminish as the criterion for good 
outcome drops towards greater disability, we do not have evidence that they invert.  
   
We found that if all categories of mRS are given equal weight and any net movement 
towards better outcome is regarded as desirable, then the onset to treatment window for 
benefit from intravenous alteplase is at least 4.5 hours, although earlier treatment is better 
than later treatment within this window. The ordinal approach11 that avoids the 
proportionality assumption gives a comparable result. Neither age nor baseline stroke 
severity modifies this relation, or if age does so it is to lengthen slightly rather than shorten 
the available time for treatment.  
 
Since the magnitude of the treatment effect appears to decrease at higher thresholds (i.e., 
two higher dichotomies show no significant benefit from iv alteplase irrespective of treatment 
initiation delay), it was anticipated that the ordinal analysis may not confirm benefit until 4.5h. 
However, there was a clear benefit for lower mRS thresholds, and only a lack of effect for 
higher mRS thresholds. In contradistinction, although alteplase has a neutral effect on mRS 
0-4 versus 5-6 and on survival, there is still a strong trend towards a time-related effect for 
these mRS divisions such that treatment initiated within 3 hours appears more useful than 
treatment initiation after 3 hours. This has biological plausibility. 
 
The observed outcomes of the isolated cohorts of patients within each treatment delay 
window or severity category (eFigures 5 and 6) give a less reliable picture of treatment 
effects than the models that incorporate all data together, because case mix varies between 
cohorts and this has a strong influence on outcome and because smaller samples deliver 
lower statistical power. 
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Our results are consistent with those of the dichotomised IPD analysis2 and with the 
conclusions of individual trials that show benefit within 4.5 hours of stroke onset, but 
especially within 3 hours.12,15 They support the conclusions of the European Stroke 
Organisation Guidelines on stroke management.19 We have not discussed here the early risk 
of fatal bleeding that is a well recognised complication of intravenous alteplase treatment,2 
because it neither has an impact on assessment of the outcome distribution nor, in the 
absence of a reliable means of identifying patients who will suffer such bleeding, on the 
decision to treat. 
 
The implications of our analysis that considers all levels of functional outcome including 
survival after stroke are clear:   
1) on average, there is an increased chance of achieving an improved level of function if 
treatment with intravenous alteplase is initiated within 4.5 hours of stroke onset; 
2) treatment benefit is greater the earlier that it is initiated;  
3) neither age nor stroke severity has a detectable impact on the relation between delay and 
treatment benefit, and particularly not on the duration of the clinically justifiable treatment 
window; and  
4) any patient who fulfils the criteria for treatment with alteplase and who wishes to optimise 
his chance of survival with optimal function should be offered treatment with intravenous 
alteplase as a matter of extreme urgency, ideally within a maximum initiation delay of 4.5 
hours.  
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Figure 1 
Relative odds of a good stroke outcome with alteplase by time to treatment, for each 
alternative definition of 'good' outcome 
 
Figure 2 
Effect of alteplase on any upwards shift in mRS, by treatment delay 
 
 
eFigure 1  
Relative odds of a good stroke outcome with alteplase, for each alternative definition of 
'good' outcome, among all randomised patients 
 
eFigure 2 
Effect of alteplase on any upwards shift in mRS, by treatment delay, age and stroke severity 
 
eFigure 3 
Effect of alteplase on any upwards shift in mRS by age and treatment delay 
 
eFigure 4 
Actual distribution of mRS* at 3−6 months by randomised treatment allocation, overall and 
by treatment delay 
 
eFigure 5 
Actual distribution of mRS* at 3−6 months by randomised treatment allocation, by stroke 
severity (among all randomised patients) 
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Figure 1: Relative odds of a good stroke outcome with alteplase by time to treatment,
for each alternative definition of 'good' outcome
In each panel the solid line represents the best linear fit between the log odds ratio for each mRS outcome among patients given alteplase
compared with patients given control (vertical axis) and treatment delay (horizontal axis).
Estimates are derived from a regression model in which alteplase, time to treatment, age and stroke severity (handled in a quadratic manner)
are included as main effects but the only treatment interaction included is with time to treatment.
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Figure 2: Effect of alteplase on any upwards shift in mRS, by treatment delay
The solid line represents the best linear fit between the log odds ratio for a good stroke outcome
among patients given alteplase compared with patients given control (vertical axis) and treatment delay
(horizontal axis).
Estimates are derived from a regression model in which alteplase, time to treatment, age and stroke
severity (handled in a quadratic manner) are included as main effects but the only treatment interaction
included is with time to treatment.
Only 198 patients (159 of whom were from IST−3) had a time from stroke onset to treatment of more than 6 hours.
The point at which the estimated treatment effect crosses 1 is therefore an extrapolation from the data.
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eFigure 1: Relative odds of a good stroke outcome with alteplase, for each alternative
definition of 'good' outcome, among all randomized patients
Odds ratio*
(95% CI)
mRS comparison
('good' vs 'bad')
Alteplase
(n=3391)
Control
(n=3365)
No. patients with
'good' outcome
Alteplase
worse
Alteplase
better
0 vs 1−6 1.40 (1.22−1.62)526 (15.5%) 391 (11.6%)
0−1 vs 2−6** 1.28 (1.15−1.42)1145 (33.8%) 965 (28.7%)
0−2 vs 3−6 1.16 (1.05−1.28)1548 (45.7%) 1413 (42.0%)
0−3 vs 4−6 1.17 (1.06−1.29)2003 (59.1%) 1864 (55.4%)
0−4 vs 5−6 0.99 (0.89−1.10)2358 (69.5%) 2344 (69.7%)
0−5 vs 6 0.93 (0.82−1.06)2727 (80.4%) 2738 (81.4%)
* Estimated from a logistic regression model stratified by trial and adjusted only for treatment allocation.
** Primary pre−specified mRS comparison.
IST−3 applied the Oxford Handicap Scale to patients at 6 months’ follow−up. We have used mortality
and functional outcome at 6 months for IST−3 patients but at 3 months for all other trials’ patients.
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eFigure 2: Effect of alteplase on any upwards shift in mRS, by treatment delay,
age and stroke severity
The solid line on each plot represents the interaction between alteplase with one of time, age or baseline NIHSS.
Each is adjusted for treatment delay (linear), age (linear) and baseline NIHSS (quadratic), and interactions between
alteplase with the other main effects (i.e. two of age, time and baseline NIHSS).
The estimated odds ratio is plotted for patients with AVERAGE levels of the other 2 baseline characteristics. The
OR for alteplase was 1.14 at the mean values of age (71 years), NIHSS (12 points) and time to treatment (4 hours).
The significance of each interaction is tested by comparing the change in deviance between two nested models
that differ only by the interaction term(s) (ie, the likelihood ratio test).
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eFigure 3: Effect of alteplase on any upwards shift in mRS by age and treatment delay
 ≤ 80 years
In each panel, the solid line represents the best linear fit between the log of the common odds ratio (vertical axis)
and treatment delay (horizontal axis). The estimates and their confidence intervals are derived from a proportional odds
logistic regression model which adjusts for allocation to rtPA, age, treatment delay and stroke severity and, through
inclusion of appropriate interaction terms, allows the log odds ratio to vary by treatment delay and for that relationship
to itself differ between patients aged 80 years or younger and patients aged over 80 years.
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eFigure 4: Actual distribution of mRS* at 3−6 months by randomized treatment
allocation, overall and by treatment delay
Mean treatment delay = 4.0 hours
Mean NIHSS = 12.0
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* mRS score ascertained at 6 months for IST−3 and 3 months for other trials.
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* mRS score ascertained at 6 months for IST−3 and 3 months for other trials. Page 6 of 6
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eFigure 1: Relative odds of a good stroke outcome with alteplase, for each alternative
definition of 'good' outcome, among all randomized patients
Odds ratio*
(95% CI)
mRS comparison
('good' vs 'bad')
Alteplase
(n=3391)
Control
(n=3365)
No. patients with
'good' outcome
Alteplase
worse
Alteplase
better
0 vs 1−6 1.40 (1.22−1.62)526 (15.5%) 391 (11.6%)
0−1 vs 2−6** 1.28 (1.15−1.42)1145 (33.8%) 965 (28.7%)
0−2 vs 3−6 1.16 (1.05−1.28)1548 (45.7%) 1413 (42.0%)
0−3 vs 4−6 1.17 (1.06−1.29)2003 (59.1%) 1864 (55.4%)
0−4 vs 5−6 0.99 (0.89−1.10)2358 (69.5%) 2344 (69.7%)
0−5 vs 6 0.93 (0.82−1.06)2727 (80.4%) 2738 (81.4%)
* Estimated from a logistic regression model stratified by trial and adjusted only for treatment allocation.
** Primary pre−specified mRS comparison.
IST−3 applied the Oxford Handicap Scale to patients at 6 months’ follow−up. We have used mortality
and functional outcome at 6 months for IST−3 patients but at 3 months for all other trials’ patients.
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eFigure 2: Effect of alteplase on any upwards shift in mRS, by treatment delay,
age and stroke severity
The solid line on each plot represents the interaction between alteplase with one of time, age or baseline NIHSS.
Each is adjusted for treatment delay (linear), age (linear) and baseline NIHSS (quadratic), and interactions between
alteplase with the other main effects (i.e. two of age, time and baseline NIHSS).
The estimated odds ratio is plotted for patients with AVERAGE levels of the other 2 baseline characteristics. The
OR for alteplase was 1.14 at the mean values of age (71 years), NIHSS (12 points) and time to treatment (4 hours).
The significance of each interaction is tested by comparing the change in deviance between two nested models
that differ only by the interaction term(s) (ie, the likelihood ratio test).
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eFigure 3: Effect of alteplase on any upwards shift in mRS by age and treatment delay
 ≤ 80 years
In each panel, the solid line represents the best linear fit between the log of the common odds ratio (vertical axis)
and treatment delay (horizontal axis). The estimates and their confidence intervals are derived from a proportional odds
logistic regression model which adjusts for allocation to rtPA, age, treatment delay and stroke severity and, through
inclusion of appropriate interaction terms, allows the log odds ratio to vary by treatment delay and for that relationship
to itself differ between patients aged 80 years or younger and patients aged over 80 years.
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eFigure 4: Actual distribution of mRS* at 3−6 months by randomized treatment
allocation, overall and by treatment delay
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Mean treatment delay = 4.0 hours
Mean NIHSS = 12.0
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* mRS score ascertained at 6 months for IST−3 and 3 months for other trials.
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